Market research
BCT.V BriaCell Therapeutics Corp
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 169M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.45
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA10778Y3023
- Market cap
- 169M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.45
About
About BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BCT.V discussion.
5 years, 5 months ago
BriaCell Therapeutics Corp is currently in a long term uptrend where the price is trading 12.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
BriaCell Therapeutics Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 78.4% to $-406K since the same quarter in the previous year.
Finally, its free cash flow fell by 58.3% to $-268K since the same quarter in the previous year.
Based on the above factors, BriaCell Therapeutics Corp gets an overall score of 3/5.